Heirloom Wealth Management Purchases 5,538 Shares of Novo Nordisk A/S (NYSE:NVO)

Heirloom Wealth Management boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 7.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 80,148 shares of the company's stock after purchasing an additional 5,538 shares during the quarter. Novo Nordisk A/S comprises about 2.1% of Heirloom Wealth Management's holdings, making the stock its 16th largest position. Heirloom Wealth Management's holdings in Novo Nordisk A/S were worth $6,894,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of NVO. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Daiwa Securities Group Inc. purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $42,000. Albion Financial Group UT raised its position in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after buying an additional 278 shares during the period. Finally, Sound Income Strategies LLC boosted its holdings in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after acquiring an additional 243 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 0.6 %

Novo Nordisk A/S stock traded down $0.52 during mid-day trading on Monday, hitting $87.45. The company's stock had a trading volume of 10,856,875 shares, compared to its average volume of 10,055,947. The firm's 50 day moving average is $95.35 and its 200 day moving average is $114.80. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The company has a market cap of $392.43 billion, a PE ratio of 28.30, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NVO shares. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Buy" and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.